Navigation Links
PharmaRoth Labs, Inc. Announces Trading Symbol Change
Date:5/1/2013

LAS VEGAS, May 1, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTCPink:  FROI) (the "Company") announced today its name change to PharmaRoth Labs, Inc. will be effective upon the open of trading on May 2, 2013.  The Company's common stock will begin trading under the new trading symbol "ROTH".

"We are pleased to announce the effectiveness of our name and trading symbol changes as they now more adequately reflects our focus on the production, marketing, and distribution of Sucanon®," stated the Company's CEO Luis Lopez , "It also completes the entry into the public marketplace and of our reorganized company so our shareholders will be more able to identify us."

About Sucanon® 
Sucanon® is a dietary supplement containing natural ingredients. In certain ex-US countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers". Pre-clinical and clinical studies conducted ex-US have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico. Sucanon® will be marketed as a dietary supplement in the US.

For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.feroindustries.com.

About PharmaRoth Labs, Inc.

PharmaRoth Labs, Inc. (OTCPink: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related
'/>"/>

SOURCE PharmaRoth Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmaRoth Labs, Inc. Files New Dietary Ingredient Notification with the US Food and Drug Administration (FDA)
2. Fero Industries, Inc. Changes Name to PharmaRoth Labs, Inc.
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. Paratek Pharmaceuticals Announces Expanded FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline
5. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
6. GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
7. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
8. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
9. Cardica Announces Fiscal 2013 Third Quarter Financial Results
10. Sensus Healthcare Announces its Exhibitor Attendance at the 45th ACMS Annual Meeting
11. Dr. David Altamira Announces New Non-Surgical Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
(Date:7/31/2014)... SUNNYVALE, Calif. , July 31, 2014  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Management Access Conference, New York, NY ... Baird Health Care Conference, New York, ... Eastern Time , Accessing Live Webcasts To access ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2
... Technologies, Inc. (Nasdaq: NTII ) and the ... have entered into a,collaboration and exclusive license agreement ... Under the terms of the agreement,Neurobiological Technologies will ... occurring protein that has been shown in animals ...
... Patient ... Population -, ... Bristol-Myers Squibb Company (NYSE: BMY ),announced today that the U.S. ... ABILIFY(R) (aripiprazole) for the,acute treatment of manic and mixed episodes associated ...
Cached Medicine Technology:Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease 2Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 9
(Date:7/31/2014)... A program for anyone looking to experience weight ... of Colorado Anschutz Health and Wellness Center (AHWC) ... transformation program. , “Extreme Weight Loss: Destination Boot ... an evidenced-based program inspired by the unscripted series “Extreme ... season, the show has participants spending their first three ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
(Date:7/31/2014)... You’re having a wonderful summer—sunning, gardening, enjoying BBQs ... chills and fever, headache, stiff neck, achey joints, and a ... it could actually be the first sign of Lyme ... is greater than you might think. Until last year, it ... U.S. annually. But the Centers for Disease Control and Prevention ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... by the Philadelphia Business Journal , Endo International, one ... agreed to settle thousands of transvaginal claims for $830 ... Systems Products Liability Litigation (MDL No. 2325). Melinda Helbock, ... A.P.C., said she agrees with the settlement and is ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces ... is simplified and predictable with fixed fees across the ... leading international provider of legal discovery management services for ... glaringly apparent that both the courts and legal counsel ... the complex pricing structure that plagues the litigation support ...
Breaking Medicine News(10 mins):Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2
... Phoebe Prince was stalked ... staple of youth culture. Keith Deltano is using comedy to fight this serious problem., ... (PRWEB) May 24, 2010 -- Phoebe Prince ... where students are being bullied to death, is comedy the appropriate vehicle to use to address ...
... ... Food & Drug Administration’s Center for Drug Evaluation and Research (CDER) will soon ... including “SPF,” “anti-aging,” or “anti-wrinkle,” according to Benjamin L. England, former 17-year FDA ... ...
... Company ... ... Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) as ... the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior Design ...
... ... been named by the United States Public Health Service Commissioned Officers Association as the 2010 ... individuals who have provided significant leadership to the advancement of the health of the American ... ...
... ... Breaks , ... -- A lawsuit has been filed in the Federal District Court of the United States for ... of current and former CVS employees alleging violations of the Fair Labor Standards Act and New ...
... ... 501(c)(3) application is filed, it has a bank account, and it even has a ... What it needs now is a logo, and it has launched a nationwide contest ... Spice House, singer Gretchen Wilson, and writer Michael Z. Williamson. , ...
Cached Medicine News:Health News:Bullying Assembly Uses Comedy to Reach Students 2Health News:Bullying Assembly Uses Comedy to Reach Students 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 2Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 4Health News:InPro Becomes AAHID Industry Partner 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 3Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 4Health News:National Employee Collective and Class Action Lawsuit Filed Against CVS 2Health News:Art Contest for New Charity With A History 2Health News:Art Contest for New Charity With A History 3Health News:Art Contest for New Charity With A History 4
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
... iMRI is a neurosurgical OR that ... diagnostic tools, including iMRI, necessary to ... iMRI, neurosurgical treatments are performed in ... designed for MR compatibility and safety, ...
... Compact is the first magnetic stimulator to ... magnetic stimulation. It is designed to provide ... the diagnostic routine (at the same time, ... since you can control operations without moving ...
... X-SIZER System is a ... for thrombus removal in ... saphenous vein grafts. ... cutter and,continuous evacuation. ...
Medicine Products: